Advanced Melanoma research hub

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This study looks at a new treatment called VO with nivolumab for advanced melanoma that has grown despite earlier treatments. It compares this combination to standard treatments chosen by your doctor for people aged 12 and over.

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

This study is looking at a new treatment called EIK1001 when given with standard treatment (Pembrolizumab) for advanced melanoma. It aims to see if this combination is safe and effective compared to Pembrolizumab alone for people whose melanoma has spread.

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This study is looking into a new treatment called brenetafusp, combined with nivolumab, for advanced melanoma. We're comparing it to current standard nivolumab treatments to see if it works better for people in the UK whose melanoma hasn't been treated before.

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

This study looks at a new drug, tebentafusp, for people with advanced melanoma that has already been treated. We want to see if tebentafusp, alone or with another drug called pembrolizumab, works better and is safer than standard treatments or best supportive care.

A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma